Aspira Pathlab

Which are the latest news on Aspira Pathlab?

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

As of 05-Sep, Aspira Pathlab & Diagnostics Ltd's stock price is rising to Rs 97.00, up 4.3%, driven by strong recent performance and increased promoter confidence. However, the company faces long-term challenges, including negative growth in operating profits and a negative EBIT.

As of 05-Sep, Aspira Pathlab & Diagnostics Ltd's stock price is rising, currently at Rs 97.00, reflecting a change of 4.0 (4.3%) upward. This increase can be attributed to several factors. The stock has outperformed the sector by 5.56% today and has shown a consecutive gain over the last two days, with a total return of 6.36% during this period. Additionally, the stock has demonstrated strong performance over the past year, generating a return of 51.56%, significantly higher than the market's average return of 1.51%.<BR><BR>Another positive indicator is the rising promoter confidence, as promoters have increased their stake in the company by 28.19% over the previous quarter, now holding 46.58% of the company. This increase in stake is often viewed as a sign of confidence in the company's future prospects.<BR><BR>However, it is important to note that despite the recent rise, the company faces challenges, including weak long-term fundamental strength, as indicated by a -166.34% CAGR growth in operating profits over the last five years and a negative EBIT of Rs. -0.59 crore. These factors suggest that while the stock is currently rising, there are underlying issues that could impact its long-term performance.

Who are in the management team of Aspira Pathlab?

The management team of Aspira Pathlab includes Pankaj Jashwant Shah (Managing Director & CEO), Arvind Karsandas Bhanushali (Executive Director), Haseeb Drabu (Chairman), and several independent directors, along with Priya Pandey as Company Secretary, all contributing to the company's governance and strategy.

The management team of Aspira Pathlab includes the following key individuals:<BR><BR>1. **Pankaj Jashwant Shah** - Managing Director & CEO<BR>2. **Arvind Karsandas Bhanushali** - Executive Director and also serves as a Non-Executive Director<BR>3. **Haseeb Drabu** - Chairman<BR>4. **Nikunj Mange** - Director<BR>5. **Mangala Radha Krishnan Prabhu** - Independent Director<BR>6. **Subhash Raghunath Salunke** - Independent Director<BR>7. **A C Mahajan** - Independent Director<BR>8. **Priya Pandey** - Company Secretary<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Aspira Pathlab do?

Aspira Pathlab & Diagnostics Ltd is a micro-cap pathology specialist established in 1973, with recent net sales of 6 Cr and a net profit of 0 Cr as of June 2026. The company has a market cap of INR 98 Cr and key financial metrics include a P/E ratio of 39.00 and a debt-equity ratio of 0.13.

Overview: <BR>Aspira Pathlab & Diagnostics Ltd is a leading pathology specialist in the healthcare services industry, operating within the micro-cap market segment.<BR><BR>History: <BR>Incorporated in July 1973, Aspira Pathlab & Diagnostics Ltd has established itself as a prominent player in the pathology sector. The latest reported quarterly results indicate net sales of 6 Cr and a net profit of 0 Cr for the period ending June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 98 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 39.00 <BR>Industry P/E: 67 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.13 <BR>Return on Equity: -3.68% <BR>Price to Book: 7.70 <BR><BR>Contact Details: <BR>Address: Flat No. 2 RD Shah Building, Shraddanand Road Ghatkopar(W) Mumbai Maharashtra : 400086 <BR>Tel: 91-22-71975756/5656 <BR>Email: info@aspiradiagnostics.com/urkalsoa <BR>Website: http://www.aspiradiagnostics.com

Who are the peers of the Aspira Pathlab?

Aspira Pathlab's peers include Jeevan Scientific, Star Imaging, Choksi Laborator, Royal Sense, Shree Pacetronix, Amkay Products, and Aakaar Medical. While Aspira has below average management risk and growth, its 1-year return of 41.50% is higher than Royal Sense's -62.36% but lower than Jeevan Scientific's 87.30%.

Peers: The peers of Aspira Pathlab are Jeevan Scienti., Star Imaging, Choksi Laborator, Royal Sense, Shree Pacetronix, Amkay Products, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, Royal Sense, Shree Pacetronix, Amkay Products, and Aakaar Medical, while Below Average management risk is found at Jeevan Scienti., Choksi Laborator, and Aspira Pathlab. Growth is Excellent at Royal Sense, Good at Star Imaging, Choksi Laborator, Shree Pacetronix, and Aakaar Medical, while Below Average growth is noted at Jeevan Scienti., Aspira Pathlab, and Amkay Products. Capital Structure is Excellent at Star Imaging, Good at Royal Sense, Shree Pacetronix, and Amkay Products, Average at Aspira Pathlab, and Below Average at Jeevan Scienti., Choksi Laborator.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Jeevan Scienti. at 87.30%, while the peer with the lowest is Royal Sense at -62.36%. Aspira Pathlab's 1-year return of 41.50% is significantly higher than Royal Sense's but lower than Jeevan Scienti.'s. Additionally, Royal Sense and Modern Diagnost. have negative six-month returns.

How big is Aspira Pathlab?

As of 31st August, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 98.00 Cr, with recent net sales of 22.62 Cr and a net profit of 2.40 Cr. The company reported shareholder's funds of 12.17 Cr and total assets of 17.46 Cr for the annual period ending in March 2025.

As of 31st August, Aspira Pathlab & Diagnostics Ltd has a market capitalization of 98.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Aspira Pathlab reported Net Sales of 22.62 Cr and a Net Profit of 2.40 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had Shareholder's Funds amounting to 12.17 Cr and Total Assets of 17.46 Cr.

Should I buy, sell or hold Aspira Pathlab & Diagnostics Ltd?

When is the next results date for Aspira Pathlab & Diagnostics Ltd?

The next results date for Aspira Pathlab & Diagnostics Ltd is 12 August 2026.

The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 12 August 2026.

Are Aspira Pathlab & Diagnostics Ltd latest results good or bad?

Aspira Pathlab & Diagnostics Ltd's latest results show strong year-on-year growth, with a 740% increase in net profit and a 13.15% rise in revenue. However, there are concerns due to a decline in both revenue and net profit compared to the previous quarter, indicating potential challenges in sustaining growth.

Aspira Pathlab & Diagnostics Ltd's latest results present a mixed picture. On one hand, the company has shown significant year-on-year growth, with a net profit of ₹0.42 crore in Q1 FY26, which is a remarkable increase of 740% compared to the same quarter last year. Revenue also rose by 13.15% year-on-year to ₹5.25 crore. Additionally, the operating margin improved to 13.9%, up 8.08 percentage points from the previous year.<BR><BR>However, the quarter-on-quarter performance raises concerns. Both revenue and net profit declined sequentially, with revenue down 9.17% and net profit down 38.24% from the previous quarter. This decline in performance suggests potential challenges in sustaining the recent growth momentum. <BR><BR>Overall, while the year-on-year improvements indicate a recovery from previous losses, the recent quarter's sequential declines point to volatility and uncertainty regarding the company's operational sustainability. Thus, the results can be seen as good in the context of year-on-year growth but concerning when considering the recent quarterly performance.

How has been the historical performance of Aspira Pathlab?

Aspira Pathlab's financial performance improved significantly from March 2024 to March 2025, with net sales rising to 22.00 Cr from 13.20 Cr, and a turnaround from losses to a profit after tax of 2.02 Cr. Key metrics such as EPS and operating profit margin also showed positive growth, indicating a strengthened financial position.

Answer:<BR>Aspira Pathlab has shown significant improvement in its financial performance from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Aspira Pathlab reported net sales of 22.00 Cr, a notable increase from 13.20 Cr in the previous year. Total operating income also rose to 22.00 Cr from 13.20 Cr, while total expenditure increased to 18.83 Cr from 14.76 Cr. This led to an operating profit (PBDIT) of 3.56 Cr, a recovery from a loss of 1.14 Cr in the prior year. Profit before tax improved to 2.07 Cr from a loss of 2.67 Cr, resulting in a profit after tax of 2.02 Cr compared to a loss of 2.67 Cr previously. The earnings per share (EPS) turned positive at 1.96, up from a negative 2.59. The operating profit margin also saw a significant turnaround, reaching 14.41% from -11.82%, while the profit after tax margin improved to 9.18% from -20.23%. On the balance sheet, total assets increased to 17.46 Cr from 14.71 Cr, with total liabilities rising to 17.46 Cr from 14.71 Cr. The book value per share improved to 7.03 from 5.07, indicating a strengthening financial position. Cash flow from operating activities remained stable at 1.00 Cr, with a closing cash equivalent of 1.00 Cr, up from none in the previous year.

Who are the top shareholders of the Aspira Pathlab?

The top shareholders of Aspira Pathlab are Deepali Arvind Bhanushali with 8.6% and Rinku Vinod Bhanushali with 8.1%. Individual investors own 60.46% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Aspira Pathlab include Deepali Arvind Bhanushali, who holds the highest promoter stake at 8.6%. Following her, the highest public shareholder is Rinku Vinod Bhanushali, with a holding of 8.1%. Additionally, individual investors collectively own a significant portion of the company, accounting for 60.46% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Is Aspira Pathlab overvalued or undervalued?

As of May 19, 2025, Aspira Pathlab is considered very attractive due to its strong performance metrics, including a PE ratio of 27.85 and a PEG ratio of 0.16, indicating it is undervalued compared to peers like Dr. Lal PathLabs and Metropolis Healthcare, despite recent underperformance against the Sensex, with a notable 107.67% return over the past year.

As of 19 May 2025, the valuation grade for Aspira Pathlab has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently undervalued based on its strong performance metrics. Key ratios include a PE ratio of 27.85, an EV to EBITDA of 16.26, and a PEG ratio of 0.16, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Aspira Pathlab's valuation stands out, particularly against companies like Dr. Lal PathLabs, which has a PE ratio of approximately 40, and Metropolis Healthcare, with an EV to EBITDA of around 25. The robust ROCE of 18.34% and ROE of 18.63% further reinforce the company's strong operational efficiency. While the stock has underperformed the Sensex in shorter time frames, its impressive 107.67% return over the past year highlights its potential for growth, supporting the conclusion that Aspira Pathlab is currently undervalued.

What is the technical trend for Aspira Pathlab?

As of April 2, 2025, Aspira Pathlab's trend is mildly bullish, with mixed signals from key indicators like MACD and Bollinger Bands across different time frames.

As of 2 April 2025, the technical trend for Aspira Pathlab has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bearish, indicating some weakness in momentum. The daily moving averages are mildly bullish, suggesting short-term support. The Bollinger Bands show a mildly bearish stance on the weekly chart but bullish on the monthly, indicating mixed signals across time frames. The KST is bearish weekly but bullish monthly, adding to the complexity of the trend. Overall, the current stance is mildly bullish, with key indicators highlighting mixed momentum and trend signals across different time frames.

Has Aspira Pathlab declared dividend?

No Dividend History Available